Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial.
Tarek HassaneinDean TaiCheng-Hai LiuTerry D BoxMyron J TongLorenzo RossaroRenee PozzaJeffrey S GlennRamsey CheungAmmar HemaidanYingchun HeCynthia BehlingXiqi HuHala MakhloufHaina FanYayun RenElaine Lay Khim ChngPing LiuJohn M VierlingPublished in: Evidence-based complementary and alternative medicine : eCAM (2022)
. This is the first US-based, multicenter and placebo-controlled clinical trial that shows statistically significant reduction in fibrosis in patients with active HCV using an antifibrotic botanical formula. This has important implications as there is an immediate need for effective antifibrotic agents in treating many chronic diseases including NASH that lead to scarring of the liver. With artificial intelligence-based methodology, qFibrosis, we may provide a more reliable way to assess the FZHY as a therapy in chronic liver diseases because of its dual anti-inflammatory and antifibrotic properties.
Keyphrases
- artificial intelligence
- clinical trial
- double blind
- placebo controlled
- phase ii
- pulmonary fibrosis
- machine learning
- big data
- anti inflammatory
- study protocol
- deep learning
- phase iii
- human milk
- open label
- hepatitis c virus
- phase ii study
- randomized controlled trial
- cross sectional
- mesenchymal stem cells
- squamous cell carcinoma
- human immunodeficiency virus
- replacement therapy